Hitiq (ASX:HIQ) said it expects up to AU$6.3 million in potential revenue from its agreement with US-based Shock Doctor, according to a June 13 filing with the Australian bourse.
On June 11, the company signed an agreement to design a mouthguard that integrates the company's Proteqt technology, with plans to produce 20,000 units this year and 100,000 units in 2026.
The non-conditional agreement is for five years with the option to be renewed for an additional five years. The product will be distributed in Australia and the UK, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.